CA1341633C - Polypeptides de type interleukine-2 - Google Patents

Polypeptides de type interleukine-2

Info

Publication number
CA1341633C
CA1341633C CA 443333 CA443333A CA1341633C CA 1341633 C CA1341633 C CA 1341633C CA 443333 CA443333 CA 443333 CA 443333 A CA443333 A CA 443333A CA 1341633 C CA1341633 C CA 1341633C
Authority
CA
Canada
Prior art keywords
leu
thr
glu
lys
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA 443333
Other languages
English (en)
Inventor
Tadatsugu Taniguchi
Masami Muramatsu
Haruo Sugano
Hiroshi Matsui
Nobukazu Kashima
Junji Hamuro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
EA Pharma Co Ltd
Original Assignee
Ajinomoto Co Inc
Japanese Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57219518A external-priority patent/JPS59140878A/ja
Priority claimed from JP57229619A external-priority patent/JPS59140882A/ja
Priority claimed from JP57234607A external-priority patent/JPS59140898A/ja
Priority claimed from JP57230371A external-priority patent/JPS59140897A/ja
Priority claimed from JP57230372A external-priority patent/JPS59139349A/ja
Priority claimed from EP83101035A external-priority patent/EP0091539B2/fr
Application filed by Ajinomoto Co Inc, Japanese Foundation for Cancer Research filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of CA1341633C publication Critical patent/CA1341633C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA 443333 1982-12-15 1983-12-15 Polypeptides de type interleukine-2 Active CA1341633C (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JP57219518A JPS59140878A (ja) 1982-12-15 1982-12-15 組換え体微生物
JP219518/1982 1982-12-15
JP229619/1982 1982-12-24
JP57229619A JPS59140882A (ja) 1982-12-24 1982-12-24 インターロイキン２活性をもつポリペプチドをコードする遺伝子
JP57234607A JPS59140898A (ja) 1982-12-27 1982-12-27 インタ−ロイキン−２の製造法
JP234607/1982 1982-12-27
JP57230371A JPS59140897A (ja) 1982-12-29 1982-12-29 インタ−ロイキン−２の製造方法
JP230371/1982 1982-12-29
JP57230372A JPS59139349A (ja) 1982-12-29 1982-12-29 ポリペプチド
JP230372/1982 1982-12-29
GB83101035.0 1983-02-03
EP83101035A EP0091539B2 (fr) 1982-03-31 1983-02-03 Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules

Publications (1)

Publication Number Publication Date
CA1341633C true CA1341633C (fr) 2013-01-29

Family

ID=27545319

Family Applications (2)

Application Number Title Priority Date Filing Date
CA000424401A Expired - Lifetime CA1341562C (fr) 1982-03-31 1983-03-24 Gene codant pour un polypeptide ayant une activite interleukine 2, adn recombinant portant ledit gene, lignees cellulaires possedant ledit adn recombinant et procede pour la preparation d'interleukine 2 en utilisant lesdites cellules
CA 443333 Active CA1341633C (fr) 1982-12-15 1983-12-15 Polypeptides de type interleukine-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA000424401A Expired - Lifetime CA1341562C (fr) 1982-03-31 1983-03-24 Gene codant pour un polypeptide ayant une activite interleukine 2, adn recombinant portant ledit gene, lignees cellulaires possedant ledit adn recombinant et procede pour la preparation d'interleukine 2 en utilisant lesdites cellules

Country Status (3)

Country Link
EP (1) EP0118617B1 (fr)
CA (2) CA1341562C (fr)
DE (1) DE3382383D1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
AU575301B2 (en) * 1982-10-08 1988-07-28 Juridical Foundation, Japanese Foundation For Cancer Research Novel vector
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
WO1985000606A1 (fr) * 1983-07-19 1985-02-14 Takeda Chemical Industries, Ltd. Il-2 humaine et son procede de preparation
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
DE3419995A1 (de) * 1984-05-29 1985-12-05 Hoechst Ag, 6230 Frankfurt Gentechnologisches verfahren zur herstellung von human-interleukin-2 und mittel zur durchfuehrung dieses verfahrens
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
IL76360A0 (en) * 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
JPH0646957B2 (ja) * 1985-03-11 1994-06-22 武田薬品工業株式会社 インタ−ロイキン−２の製造方法
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
JP3241748B2 (ja) * 1991-04-11 2001-12-25 川崎製鉄株式会社 加工性と焼入れ性に優れた鋼材及びその製造方法
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001040311A1 (fr) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Proteine fusionnee de chimiokine slc-il2
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
AU2004287879C1 (en) 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP3443979B2 (fr) 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris Régime posologique d'il-2 pour le traitement du lupus érythémateux systémique
EP3013355B1 (fr) 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 pour utilisation dans le traitement de la maladie d'alzheimer et de troubles associes
EP2918285A1 (fr) 2014-03-11 2015-09-16 Université Pierre et Marie Curie (Paris 6) Interleukin-2 pour traiter une allergie alimentaire
ES2982752T3 (es) 2015-10-22 2024-10-17 Iltoo Pharma Composiciones farmacéuticas de il-2
IL263874B2 (en) 2016-06-22 2025-02-01 David Klatzmann Genetically modified T lymphocytes
EP3752178A1 (fr) 2018-02-16 2020-12-23 Iltoo Pharma Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
EP3836954B1 (fr) 2018-08-13 2025-05-07 Iltoo Pharma Combinaison d'interleukine-2 avec un inhibiteur de l'interleukine 1, conjugués et leurs utilisations thérapeutiques
EP3880838B1 (fr) 2018-11-15 2024-12-25 The Board of Trustees of the Leland Stanford Junior University Compositions et méthodes de pronostic et de classification pour la prééclampsie
US20230036793A1 (en) 2019-12-12 2023-02-02 Iltoo Pharma Interleukin 2 chimeric constructs
US20230090069A1 (en) 2020-03-06 2023-03-23 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
CN118414160A (zh) 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
AU2022477937A1 (en) 2022-09-12 2025-04-10 Assistance Publique - Hôpitaux De Paris Interleukin-2 for use in treating autism spectrum disorder
WO2024121173A1 (fr) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Interleukine-2 humaine à faible dose pour traitement de la sclérose latérale amyotrophique dans un sous-groupe de patients
WO2025032158A1 (fr) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Méthode de traitement de tauopathies
WO2026159300A1 (fr) 2025-01-24 2026-07-30 Iltoo Pharma Anticorps m3c65 et ses dérivés pour le ciblage de l'inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58116498A (ja) * 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
AU579089B2 (en) * 1983-02-08 1988-11-17 Biogen, Inc. Human interleukin-2-like polypeptides
IL71275A0 (en) * 1983-03-21 1984-06-29 Sparamedica Ag Human interleukin-2-and its preparation
WO1985000817A1 (fr) * 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii

Also Published As

Publication number Publication date
EP0118617A3 (en) 1985-11-13
DE3382383D1 (en) 1991-09-26
EP0118617B1 (fr) 1991-08-21
EP0118617A2 (fr) 1984-09-19
CA1341562C (fr) 2007-11-27

Similar Documents

Publication Publication Date Title
EP0118617B1 (fr) Interleukine-2 polypeptides
KR940010865B1 (ko) 종양 괴사 인자의 생산 방법 및 종양 괴사 인자의 수율을 증가시키는 방법
EP0043980B1 (fr) Interferon A mature de leucocytes humains, procédé pour sa production microbienne, produits intermédiaires correspondents et compositions le contenants
KR860001558B1 (ko) 인터페론의 제조방법
EP0218825B1 (fr) Mutéines d'interféron-bêta sans cystéine, leur préparation, compositions contenant ces mutéines et gènes structuraux, vecteurs et organismes propres à l'utilisation pour la préparation desdites mutéines et leur production
EP0077670B1 (fr) Interféron humain immunisé
US4853332A (en) Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
EP0091539B1 (fr) Gène codant pour interleukin-2 polypeptide, ADN recombinant portant ledit gène, lignées cellulaires possédant le recombinant ADN et procédé pour la préparation d'interleukin-2 utilisant lesdites cellules
US4588585A (en) Human recombinant cysteine depleted interferon-β muteins
USRE33653E (en) Human recombinant interleukin-2 muteins
Liang et al. Studies of structure-activity relationships of human interleukin-2.
EP0751220A1 (fr) Protéine hautement purifiée, sa production et utilisation
HU202921B (en) Process for producing coding dns for human tumor necrosis factor the corresponding polypeptide with utilizing them and pharmaceutical compositions containing this polypeptide as active component
EP0456332B1 (fr) Interleukine-1 purifiée et ADN codant pour l'interleukine-1 et leur préparation, vecteurs contenant cet ADN et leur préparation et utilisation dans la transformation des hôtes permettant l'expression d'interleukine-1
JPS6363199B2 (fr)
US5700913A (en) Unglycosylated human interleukin-2 polypeptides
EP0413818B1 (fr) Procede de production d'un polypeptide du facteur chimiotactique neutrophile humain
AU621051B2 (en) Method for purifying granulocyte-macrophage colony stimulating factor
EP0267795A2 (fr) Mutéines de l'interleukine-2 de la souris
EP0147175A2 (fr) Polypeptides de base et méthode pour leur préparation
EP0232707A1 (fr) Facteur humain d'augmentation de la croissance de cellules hématopoiétiques
EP0431042A1 (fr) Un procede de preparation d'un polypeptide de facteur chimiotactique neutrophile humain actif.
FI82714C (fi) Foerfarande foer framstaellning av en transformerad stam av e.coli, som foermaor expressera ett humant moget leukocytinterferon.
KR870000511B1 (ko) 발현 비히클의 제조방법
KR870000510B1 (ko) 형질전환된 미생물의 제조방법

Legal Events

Date Code Title Description
U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241205